Evaluating Cell Adhesion Proteins for Pharmacological Interventions ID: 2020-064

A novel approach to enhance drug discovery by evaluating cell-cell interactions and adhesion proteins using flow cytometry.

Technology Overview

This technology introduces a groundbreaking method for the high-throughput evaluation of cell adhesion proteins, crucial for pharmacological interventions. By leveraging bacterial technology and flow cytometry, it enables the rapid assessment of protein interactions, focusing on improving therapeutic strategies through the manipulation of tight junctions and cell adhesion mechanisms. This approach is particularly beneficial for diseases where cell-cell interactions play a significant role, such as glioblastoma and inflammatory bowel disease.

Key Advantages

• Enables high-throughput evaluation of cell-cell interactions
• Facilitates rapid analysis and assessment of protein interactions using flow cytometry
• Targets specific proteins, such as claudins, to improve drug delivery routes
• Provides a novel approach to manipulate tight junctions and cell adhesion for drug discovery

Problems Addressed

• Limitations in current drug discovery processes related to the evaluation of cell-cell interactions
• Challenges in therapeutic drug delivery, particularly across the blood-brain barrier
• Unmet needs in the treatment of diseases like glioblastoma and inflammatory bowel disease

Market Applications

• Cancer treatment, specifically for improving drug delivery to brain tumors
• Inflammation control by targeting cell adhesion mechanisms
• Therapeutic interventions for viral infections through manipulation of cell adhesion properties

Additional Information

Technology ID: 2020-064
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025